Study #2022-0275
A Phase IB/2 Study of OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors and Activating Mutations in the RAS Pathway (Phase 1B) in Patients with Advanced NRAS-Mutated Melanoma (Phase 2)
MD Anderson Study Status
Not Accepting
Treatment Agent
OKI-179 + binimetinib
Description
The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
RAS Mutation, NRAS Gene Mutation, Melanoma
Study phase:
Physician name:
Rodabe Amaria
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.